Antonella Perotti

741 total citations
25 papers, 591 citations indexed

About

Antonella Perotti is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Antonella Perotti has authored 25 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Antonella Perotti's work include Cancer Treatment and Pharmacology (14 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Antonella Perotti is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Antonella Perotti collaborates with scholars based in Italy, Switzerland and Germany. Antonella Perotti's co-authors include Cristiana Sessa, Luca Gianni, Curzio Rüegg, Agnese Mariotti, Giuseppe Capri, Sara Cresta, Silvia Marsoni, Cristina Noberasco, Flavia Zanaboni and José Jimeno and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Antonella Perotti

25 papers receiving 576 citations

Peers

Antonella Perotti
Anita S. Jorna Netherlands
Arezoo Astanehe Canada
Carmen Ghilardi Italy
Alexander P. Adler United States
Allen Saliganan United States
Carlos Mackintosh Spain
Jason Kirk United States
Helene Tuft Stavnes Norway
Tetsukan Woo Japan
Clara Salamanca Canada
Anita S. Jorna Netherlands
Antonella Perotti
Citations per year, relative to Antonella Perotti Antonella Perotti (= 1×) peers Anita S. Jorna

Countries citing papers authored by Antonella Perotti

Since Specialization
Citations

This map shows the geographic impact of Antonella Perotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonella Perotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonella Perotti more than expected).

Fields of papers citing papers by Antonella Perotti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonella Perotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonella Perotti. The network helps show where Antonella Perotti may publish in the future.

Co-authorship network of co-authors of Antonella Perotti

This figure shows the co-authorship network connecting the top 25 collaborators of Antonella Perotti. A scholar is included among the top collaborators of Antonella Perotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonella Perotti. Antonella Perotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bauer, Todd M., Armando Santoro, Chia‐Chi Lin, et al.. (2023). Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007353–e007353. 24 indexed citations
2.
Fiedler, Walter, Herbert Stoeger, Antonella Perotti, et al.. (2018). Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open. 3(4). e000381–e000381. 14 indexed citations
3.
Sessa, Cristiana, Gianluca Del Conte, Sara Cresta, et al.. (2013). Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. Investigational New Drugs. 31(5). 1236–1243. 14 indexed citations
4.
Ong, Michael, Gianluca Del Conte, Rastislav Bahleda, et al.. (2013). A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2535–2535. 3 indexed citations
5.
Perotti, Antonella, Cristiana Sessa, N. Colombo, et al.. (2010). Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). 5050–5050. 1 indexed citations
6.
Soria, J.C., Rastilav Bahleda, Benjamin Besse, et al.. (2010). 386 Phase I study of the vascular disrupting agent (VDA) ombrabulin (Ob) in combination with taxanes (T) and platinum salts (PS) in patients (pts) with advanced solid tumors. European Journal of Cancer Supplements. 8(7). 122–123. 2 indexed citations
7.
Perotti, Antonella, Cristiana Sessa, Andrea Mancuso, et al.. (2009). Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Annals of Oncology. 20(4). 741–745. 56 indexed citations
8.
Sessa, Cristiana, Antonella Perotti, Cristina Noberasco, et al.. (2008). Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. European Journal of Cancer. 45(7). 1153–1161. 41 indexed citations
9.
10.
Sessa, Cristiana, Antonella Perotti, Anna Lladó, et al.. (2007). Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Annals of Oncology. 18(9). 1548–1553. 37 indexed citations
11.
Mariotti, Agnese, Antonella Perotti, Cristiana Sessa, & Curzio Rüegg. (2007). N-cadherin as a therapeutic target in cancer. Expert Opinion on Investigational Drugs. 16(4). 451–465. 101 indexed citations
12.
Bombardieri, Emilio, Angela Coliva, Claudio Chiesa, et al.. (2007). Phase I study with antifibronectin I-131 L19-SIP: First dosimetric and therapeutic results. 48. 2 indexed citations
13.
Cresta, Sara, Antonella Perotti, Laura Merlini, et al.. (2006). Combination of paclitaxel and two schedules of gefitinib in patients with metastatic breast cancer. Journal of Clinical Oncology. 24(18_suppl). 10599–10599. 6 indexed citations
14.
Perotti, Antonella, Lucia Viganò, Elisa Gallerani, et al.. (2006). Phase Ib pharmacokinetic (PK) and pharmacodynamic (PD) study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine (CAPE). Journal of Clinical Oncology. 24(18_suppl). 3065–3065. 8 indexed citations
15.
Sessa, Cristiana, Antonella Perotti, Angelica Fasolo, et al.. (2006). An enriched phase I, pharmacokinetic and pharmacodynamic study of the N-cadherin (NCAD) cyclic competitive binder exherin (ADH-1) in patients with solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3042–3042. 6 indexed citations
16.
Bourbouloux, Emmanuelle, et al.. (2006). Phase I study of intravenous (IV) milataxel in adult patients with advanced malignant tumors. Journal of Clinical Oncology. 24(18_suppl). 2037–2037. 3 indexed citations
17.
Sessa, Cristiana, Filippo de Braud, Antonella Perotti, et al.. (2005). Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. Journal of Clinical Oncology. 23(9). 1867–1874. 135 indexed citations
18.
Sessa, Cristiana, Antonella Perotti, Emanuela Salvatorelli, et al.. (2004). Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. European Journal of Cancer. 40(4). 563–570. 9 indexed citations
19.
Perotti, Antonella, Sara Cresta, Giacomo Grasselli, et al.. (2003). Cardiotoxic effects of anthracycline–taxane combinations. Expert Opinion on Drug Safety. 2(1). 59–71. 17 indexed citations
20.
Perotti, Antonella, Sara Cresta, Giacomo Grasselli, et al.. (2003). Cardiotoxic effects of anthracycline?taxane combinations. Expert Opinion on Drug Safety. 2(1). 59–71. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anita S. Jorna Breakdown of academic impact, for papers by Arezoo Astanehe Breakdown of academic impact, for papers by Carmen Ghilardi Breakdown of academic impact, for papers by Alexander P. Adler Breakdown of academic impact, for papers by Allen Saliganan Breakdown of academic impact, for papers by Carlos Mackintosh Breakdown of academic impact, for papers by Jason Kirk Breakdown of academic impact, for papers by Helene Tuft Stavnes Breakdown of academic impact, for papers by Tetsukan Woo Breakdown of academic impact, for papers by Clara Salamanca
Rankless by CCL
2026